標的型経口抗がん剤治療の最初の8週間の患者の症状,自信,および遵守
Amna Rizvi-Toner1,2, Antoinette B Coe3, Christopher R Friese4
1Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA. arizvito@umich.edu.
まとめ
経口抗がん剤 (OAA) を服用している患者は重度の症状を経験しましたが,それらを管理する自信とOAAの遵守は時間の経過とともに改善しました. 症状と自信の関係を特定することは,OAA療法に対する臨床的サポートを導くことができます.
科学分野:
- 腫瘍学 腫瘍学
- 薬理学 薬理学とは
- 患者の報告したアウトカム
背景:
- 標的型経口抗がん剤 (OAA) は,がん治療においてますます使用されています.
- 症状の負担と自己管理を含む患者の経験を理解することは,OAA治療の最適化に不可欠です.
研究 の 目的:
- 標的型OAA.A.S.に対する患者の初期体験を調査する.
- 症状の重度が患者の自信とOAAsの遵守にどのように影響するか検討する.
主な方法:
- OAA治療の最初の8週間に59人の患者を対象とした長期的前向きコホート研究.
- 3つのタイムポイントでオンラインで収集された患者報告結果測定値 (PROMs).
- 統計分析には,記述的統計,ロジスティック回帰,および混合効果のロジスティック回帰が含まれていました.
主要な成果:
- 重篤な症状,特に疲労と眠気は頻繁に報告されました.
- 8週間の研究期間中,症状の管理に対する患者の自信は増加しました.
- 大半は高い遵守率 (75-80%) を報告したが,20-25%は最適以下の遵守率であった;信頼性は年齢と関連し,症状の重症度と逆相関していた.
結論:
- OAA治療中に症状の管理に対する自信は向上しますが,重度の症状は持続します.
- 患者の有意な割合は,自己報告された高い遵守にもかかわらず,最適以下のOAA遵守を示しています.
- 症状の重症度,自信,および遵守の間の患者特有の関係を特定することは,標的化された臨床サポートに不可欠です.
関連する概念動画
Oral Hypoglycemic Agents: Glinides
695
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
695
Oral Hypoglycemic Agents: Sulfonylureas
1.2K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
694
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
694
Anticholinesterase Agents: Poisoning and Treatment
1.7K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.7K
Confidence Coefficient
10.7K
The confidence coefficient is also known as the confidence level or degree of confidence. It is the percent expression for the probability, 1-α, that the confidence interval contains the true population parameter assuming that the confidence interval is obtained after sufficient unbiased sampling; for example, if the CL = 90%, then in 90 out of 100 samples the interval estimate will enclose the true population parameter. Here α is the area under the curve, distributed equally under...
10.7K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
597
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
597


